Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alar PharmaceuticalsROCO:6785 -4.81%56 Cash Ratio is 38.22 as of Jun. 2026, which is at its 10-year median of 38.22. GuruFocus rates ROCO:6785 with a GF Score™ of 56/100 and a GF Value™ of NT$92.17 (Fairly Valued). The stock has 1 warning sign investors should review. Among 965 Drug Manufacturers companies, Alar Pharmaceuticals ranks better than 99.38% on this metric.
Alar Pharmaceuticals has a Cash Ratio of 38.22. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Alar Pharmaceuticals's Cash Ratio or its related term are showing as below:
ROCO:6785'
s Cash Ratio Range Over the Past 10 Years
Min: 1.3 Med: 38.22 Max: 141.42
Current: 38.22
During the past 9 years, Alar Pharmaceuticals's highest Cash Ratio was 141.42. The lowest was 1.30. And the median was 38.22.
ROCO:6785's Cash Ratio is ranked better than 99.38% of 965
companies
in the Drug Manufacturers industry
Industry Median: 0.57
vs ROCO:6785: 38.22
Alar Pharmaceuticals (ROCO:6785) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Alar Pharmaceuticals Cash Ratio Related Terms
Alar Pharmaceuticals Cash Ratio Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals (ROCO:6785) has a Cash Ratio of 38.22 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alar Pharmaceuticals and its competitors. This is near median its historical median of 38.22. Over the past decade, Alar Pharmaceuticals' Cash Ratio has ranged from 1.30 to 141.42. According to the industry distribution chart, Alar Pharmaceuticals ranks #6 out of 965 companies in the Drug Manufacturers industry, placing it in the top 0.59999999999999%.
Is Alar Pharmaceuticals' Cash Ratio too high?
Alar Pharmaceuticals' current Cash Ratio of 38.22 is near median its 10-year median of 38.22. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 141.42. The Drug Manufacturers industry median Cash Ratio is 0.57. Alar Pharmaceuticals' value of 38.22 is 6605.3% above this industry median. Based on the distribution chart, Alar Pharmaceuticals ranks #6 out of 965 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #6 out of 965 companies for Cash Ratio. This places Alar Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.57. Alar Pharmaceuticals' value of 38.22 is 6605.3% above this benchmark. Historically, Alar Pharmaceuticals' own Cash Ratio has ranged from 1.30 to 141.42 over the past decade. While the company's 10-year median is 38.22 vs. the industry median of 0.57, Alar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.57, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alar Pharmaceuticals's current Cash Ratio of 38.22 is 6605.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current Cash Ratio is 38.22, which is near median its own 10-year median of 38.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Fairly Valued. The stock's GF Value™ is NT$92.17, compared to a current price of NT$99.00 — trading 7.4% above its estimated fair value. The current Cash Ratio is 38.22, which is near median its 10-year median of 38.22 and 6605.3% above the Drug Manufacturers industry median of 0.57. Alar Pharmaceuticals' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Cash Ratio is 38.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$99.00 is trading 7.4% above its estimated GF Value™ of NT$92.17.
GuruFocus considers Alar Pharmaceuticals to be Fairly Valued.
Key valuation signals for ROCO:6785:
Cash Ratio: 38.22 (near median its 10-year median of 38.22)
GF Value™: NT$92.17 vs. price of NT$99.00 (7.4% above fair value)
Industry Position: 6605.3% above the Drug Manufacturers median (#6 of 965)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
56GF Score
Get the complete analysis for ROCO:6785
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
